Aortic Diseases

Subscribe to Selected New Research on Aortic Diseases

219 relevant articles (12 outcomes, 23 trials/studies) found for this Disease

Description: Pathological processes involving any part of the AORTA.

Also Known As:

Aortic Disease; Disease, Aortic; Diseases, Aortic

Relationship Network

Disease Context: Research Results

Cardiovascular Diseases: 18509

Vascular Diseases: 7181

Aortic Diseases: 219

Aortic Aneurysm: 1525

Aortitis: 138

Leriche Syndrome: 48

Aortic Arch Syndromes: 7

Related Diseases

1.	Abdominal Aortic Aneurysm
2.	Stroke (Strokes)
3.	Atherosclerosis (Atheroma)
4.	Hypertension (High Blood Pressure)
5.	Heart Diseases (Heart Disease)

Experts

1.	Eggebrecht, Holger: 2 articles (01/2008 - 04/2006)
2.	Erbel, Raimund: 2 articles (01/2008 - 04/2006)
3.	Sundt, Thoralf M: 2 articles (01/2008 - 08/2003)
4.	Reidy, J F: 2 articles (09/2007 - 07/2000)
5.	Cheng, Stephen W K: 2 articles (04/2006 - 03/2003)
6.	Herold, Ulf: 2 articles (04/2006 - 12/2005)
7.	Domanovits, Hans: 2 articles (06/2002 - 04/2002)
8.	Röggla, Martin: 2 articles (06/2002 - 04/2002)
9.	Dapunt, Otto E: 1 article (04/2008)
10.	Südkamp, Michael: 1 article (04/2008)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Aortic Diseases:

1.	GadoliniumIBA 07/01/1999 - "CONCLUSION: Optimized single-dose breath-hold gadolinium-enhanced 3D MR angiography is superior to double-dose non-breath-hold 3D MR angiography for evaluation of thoracic aortic disease." 07/01/1999 - "OBJECTIVE: The purpose of this study was to compare single-dose (0.1 mmol/kg) breath-hold gadolinium-enhanced three-dimensional (3D) MR angiography and double-dose (0.2 mmol/kg) non-breath-hold 3D MR angiography for evaluation of thoracic aortic disease" 04/01/2006 - "Gadolinium (Gd)-enhanced three-dimensional breath-hold magnetic resonance cardiac-synchronized angiography was performed in 13 patients suspected or known to have thoracic aortic disease" 11/01/1999 - "INTRODUCTION: We investigated the diagnostic accuracy of gadolinium-enhanced 3D MRA in the assessment of thoracic aortic diseases" 01/01/1997 - "PURPOSE: To evaluate gadolinium-enhanced three-dimensional magnetic resonance (MR) angiography for thoracic aortic disease and to compare this technique with conventional thoracic MR imaging" Order ALL the reference details at left...
2.	CollagenIBA 06/01/2001 - "This study demonstrates the integral role of type I collagen in the biomechanical and functional properties of the aorta and may help to elucidate the role of collagen in the development of aneurysmal aortic disease or dissection." 01/01/2000 - "Thoracic aortas of 56 individuals (age 45-74 years), none of whom suffered from aortic disease, were studied by immunoelectron microscopy of elastin, collagen types I, III, IV, V, and VI, fibronectin, and fibrillin-1, and by ultrastructural histochemistry of proteoglycans, which were further characterized by enzymatic digestion" Order ALL the reference details at left...
3.	Collagen Type I (Type I Collagen)IBA 06/01/2001 - "This study demonstrates the integral role of type I collagen in the biomechanical and functional properties of the aorta and may help to elucidate the role of collagen in the development of aneurysmal aortic disease or dissection." Order ALL the reference details at left...
4.	Adrenergic Receptors (Adrenergic Receptor)IBA 11/01/1999 - "Life expectancy has markedly improved due to the widespread use of beta-adrenergic receptor inhibitors and improved surgical management of the aortic disease." Order ALL the reference details at left...
5.	Genetic Markers (Genetic Marker)IBA 06/01/2007 - "Currently under investigation are the genetic markers linked to aortic disease that may help to identify patients at risk for their development prior to clinical presentation" Order ALL the reference details at left...
6.	ElastinIBA 06/01/1989 - "This study was done to determine if alterations in systemic elastin metabolism could be detected in patients with different types of infrarenal aortic disease by quantitating urinary LVP" 10/01/1987 - "Smooth muscle cell regulation of elastin metabolism may be important in determining why some patients have AAA and others have occlusive aortic disease develop." 06/01/1989 - "Recent evidence indicates that metabolism of elastin may be altered in patients with different types of infrarenal aortic disease and that the phenotypic expression of aortic disease may be dependent on the balance between aortic elastase and antiprotease activity" 08/01/1987 - "In order to study the role of elastin in arteries with respect to hypertension and hypertensive arterial disease, aortic elastin content and elastase-like enzyme activity were examined and compared in stroke-prone spontaneously hypertensive rats (SHRSP), which show malignant hypertension, and Wistar-Kyoto normotensive rats (WKY)" 01/01/2000 - "Thoracic aortas of 56 individuals (age 45-74 years), none of whom suffered from aortic disease, were studied by immunoelectron microscopy of elastin, collagen types I, III, IV, V, and VI, fibronectin, and fibrillin-1, and by ultrastructural histochemistry of proteoglycans, which were further characterized by enzymatic digestion" Order ALL the reference details at left...
7.	Pancreatic Elastase (Elastase)IBA 04/01/1987 - "Aortic elastase modified by local antiprotease activity (elastase/a-1-antitrypsin) was significantly higher in patients with a ruptured AAA compared with patients with an elective AAA or occlusive aortic disease: 241 nanograms per milligram of tissue in AAA-rupture versus 57 nanograms per milligram of tissue in AAA-elective versus 32 nanograms per milligram of tissue for occlusive (p less than 0.003)" 06/01/1989 - "Recent evidence indicates that metabolism of elastin may be altered in patients with different types of infrarenal aortic disease and that the phenotypic expression of aortic disease may be dependent on the balance between aortic elastase and antiprotease activity" 02/01/1988 - "These data suggest that the ratio between elastase and its major serum inhibitor, alpha 1-antitrypsin, is significantly altered in the aortic wall in different types of infrarenal aortic disease" 02/01/1988 - "Elastase modified by alpha 1-antitrypsin (elastase/alpha 1-antitrypsin) increased significantly as the type of aortic disease changed from occlusive to aneurysmal disease" 08/01/1987 - "In order to study the role of elastin in arteries with respect to hypertension and hypertensive arterial disease, aortic elastin content and elastase-like enzyme activity were examined and compared in stroke-prone spontaneously hypertensive rats (SHRSP), which show malignant hypertension, and Wistar-Kyoto normotensive rats (WKY)" Order ALL the reference details at left...
8.	C-Reactive ProteinIBA 06/01/2002 - "C-reactive protein and mortality in patients with acute aortic disease." 12/01/2008 - "pneumoniae antibodies and high-sensitivity C-reactive protein (hsCRP) levels are associated with BMIPatients and Methods : The study population consisted of 174 patients with symptomatic carotid stenosis, abdominal aortic aneurysm or occlusive aortic disease" 09/01/1987 - "In 20 patients with stenosing aortic disease the C-reactive protein was 28 +/- 8 mg/l, alpha 1-proteinase inhibitor 1.65 +/- 0.11 g/l and ceruloplasmin 0.35 +/- 0.03 g/l" Order ALL the reference details at left...
9.	Messenger RNA (mRNA)IBA 06/01/1995 - "The purpose of the present study was to assess vascular cell adhesion molecule-1 (VCAM-1) mRNA expression and the properties of soluble VCAM-1 in patients with atherosclerotic aortic disease" 07/01/2008 - "Neonatal intravenous injection of a retroviral vector normalized MMP-12 and cathepsin S mRNA levels and prevented aortic disease" Order ALL the reference details at left...
10.	Losartan (Cozaar)FDA Link 10/01/2007 - "Recent studies in an FBN1-targeted mouse model of MFS with aortic disease similar to that seen in humans showed that treatment with losartan normalized aortic root growth and aortic wall architecture" Order ALL the reference details at left...

Therapies and Procedures

1.	Stents 07/01/2007 - "CONCLUSIONS: The early and mid-term results of endovascular stent-grafting for the treatment of chronic and acute thoracic aortic diseases showed a good outcome and low rate of complications" 06/01/2004 - "BACKGROUND: Endovascular stent grafting (EVSG) has emerged as a new treatment for aortic disease and has recently been applied to the treatment of acute blunt aortic injury (BAI)" 01/01/2007 - "The frequency of complications was apparently decreased after clinical application of the unibody Z-stent in SG treatment for thoracic and thoracoabdominal aortic disease." 01/01/2007 - "The unibody Z-stent was applied to treat thoracic and thoracoabdominal aortic disease in seven patients" 10/01/2006 - "CONCLUSIONS:Thoracic aortic stent grafting for acute thoracic aortic disease is feasible and has a high success rate, with good short-to-midterm results" Order ALL the reference details at left...
2.	Transplants (Transplant) 04/01/2005 - "PATIENTS: All adult patients with aortic disease that involved the distal aortic arch, the descending thoracic aorta, or the thoracoabdominal aorta who underwent resection and graft replacement of the diseased segment via LHB or TCA at our institution from 1989 to 2001 are included in this study" 08/01/2007 - "Patients with combined valvular-aortic disease undergo surgical reconstruction of the aortic root with a valved composite graft" 06/01/2007 - "Four cases of proximal endostent instability after endovascular tube graft treatment of thoracic aortic disease using the TAG Gore system are reported" 09/01/2005 - "PURPOSE: To prospectively evaluate the detection of the artery of Adamkiewicz at magnetic resonance (MR) angiography and the effect such detection has on outcome after surgical graft placement in a series of patients with thoracoabdominal aortic disease" 10/01/2003 - "BACKGROUND: Marfan patients who received composite graft replacement for proximal aortic disease frequently require late reoperation" Order ALL the reference details at left...
3.	Emergency Treatment 06/01/2003 - "CONCLUSION: endoluminal repair of thoracic aortic disease requiring urgent/emergency treatment has encouraging results with low morbidity and mortality rates compared with open surgery" 01/01/2008 - "PURPOSE: To investigate the long-term outcome and efficacy of emergency treatment of acute aortic diseases with endovascular stent-grafts" 05/01/2002 - "PURPOSE: To investigate the safety and efficacy of emergency treatment of acute aortic diseases with endovascular stent grafts" 08/01/2002 - "OBJECTIVE: The aim of this study was to evaluate the feasibility, safety, and effectiveness of endovascular stent-graft placement for the emergency treatment of acute descending thoracic aortic disease" 05/01/2002 - "METHODS: In 11 patients (median age 55 years, range 18 - 85) with acute complications of descending aortic diseases endovascular emergency treatment was performed: traumatic aortic rupture (n = 4), penetrating ulcer with aortobronchial fistula or hematothorax (n = 4), acute type B dissection (n = 2, one with penetration, one with subacute mesenteric ischemia), and symptomatic aneurysm of the thoracic aorta (n = 1) with pain and diameter progression" Order ALL the reference details at left...
4.	Endarterectomy (Thromboendarterectomy) 06/01/1995 - "CONCLUSION: Transaortic renal endarterectomy is an acceptably safe and effective adjunctive technique in selected patients with combined aortic disease and ASRD." 06/01/1995 - "PURPOSE: A study was undertaken to assess the safety and efficacy of transaortic endarterectomy for orificial atherosclerotic renovascular disease (ASRD), particularly in conjunction with surgery for concomitant aortic disease" 12/01/1990 - "In seven patients transaortic endarterectomy was performed as a secondary procedure during the course of complex reconstruction of aneurysmal or occlusive aortic disease" 02/01/2004 - "Aortoiliac disease can be either treated with surgery-endarterectomy for localized aortic disease or with bypass graft placement for more extensive aortoiliac disease--or with percutaneous transluminal angioplasty (PTA), which has become an established method" Order ALL the reference details at left...
5.	Homologous Transplantation (Allograft) 09/01/2001 - "With broader indications for renal transplantation and improved allograft survival, it is anticipated that the problem of aortic disease in the post-transplant patient will be encountered with increasing frequency" 10/01/2005 - "METHODS: Twenty-two patients (age 53 +/- 14 years, range 31-80 years) from April 2002 to July 2003 underwent aortic root replacement with a CryoLife SynerGraft aortic valve conduit homograft (CryoLife Inc, Kennesaw, Ga) for congenital or acquired aortic valve disease, aortic aneurysm with aortic valve disease, or native or prosthetic aortic valve endocarditis" 04/22/2004 - "METHODS: From October 1994 to November 2003, 20 cases of Ross procedure were performed to treat with congenital aortic disease, Male: 15 cases; Female: 5 cases; age: 25 years; Diagnosis: congenital heart disease (CHD), aortic abnormalities: 12 cases; aortic valve prolapse: 5 cases; aortic valve hypogenesis: 3 cases; combined with subacute bacterial endocarditis (SBE): 4 cases, and ventricle septal defect (VSD): 2 cases; UCG showed aortic stenosis(AS) and/or aortic insufficience (AI) (moderate to severe), Left ventricle diastole diameter (LVDD): (60.51 +/- 11.87) mm, the grade pressure across aortic valve: (27.04 +/- 6.80) mmHg, heart function (NYHA): Class II: 13 cases; Class III: 3 cases; all cases were performed under CPB and moderate hypothermia, the operation procedure was following: (1) taking off auto-pulmonary artery valve; (2) removing dysfunctional aortic valve and auto-transplantation of pulmonary valve on aortic root; (3) putting a pulmonary homograft to rebuild right ventricular outflow tract" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Aortic Diseases

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 12 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>